|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 01, 2017 ) Frontier Pharma Market: Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.
This has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy.
Browse market data tables and 47 figures evenly distributed through 88 pages and in-depth TOC on Frontier Pharma Market Report@ https://www.marketreportsworld.com/10293448
Scope of this Frontier Pharma Market Research Report:
· The escalating T2DM public healthcare need has resulted in a competitive market landscape
Ø What is the pathophysiology of Frontier Pharma Market T2DM?
Ø What are the common co-morbidities and complications?
Ø How has the emergence of new drug classes in the past decade impacted the treatment algorithm?
Ø What are the most significant unmet needs within the market?
· The T2DM pipeline is large and innovative
Ø Which molecule types and molecular targets are most prominent within the pipeline?
Ø Which first-in-class targets are most promising?
Ø How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
· The Frontier Pharma Market T2DM deals landscape is highly active
Ø Do T2DM products attract high deal values?
Ø Which molecule types and molecular targets dominate the deals landscape?
Ø Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Get a Sample PDF of Frontier Pharma Market Research Report@ https://www.marketreportsworld.com/enquiry/request-sample/10293448
The emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the treatment algorithm.
Major TOC included in this Frontier Pharma Market Report:
· The Case for Innovation
· Clinical and Commercial Landscape
· Assessment of Pipeline Product Innovation
· Frontier Pharma Market Type 2 Diabetes Mellitus Signaling Network, Disease Causation and Innovation Alignment
· First-in-Class Target and Pipeline Program Evaluation
· Strategic Consolidations
Purchase Frontier Pharma Market Report@ https://www.marketreportsworld.com/purchase/10293448
Price of Report: $6995 (Single User Licence)
Key Reasons to Purchase this Frontier Pharma Market Report:
· Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
· Identify leading products and companies within the Frontier Pharma Market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.
· Recognize innovative pipeline trends by analysing therapies by stage of development, molecule type and molecular target.
· Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the Frontier Pharma Market T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
· Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
Enquiry for Discount before Buying@ https://www.marketreportsworld.com/enquiry/pre-order-enquiry/10293448
Markets Reports World
Ameya Pingaley
+1 408 520 9750
sales@marketreportsworld.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
